Arthur D Little forms drug delivery deal with Vectura
This article was originally published in Clinica
Executive Summary
Arthur D Little (ADL) is to merge its inhalation drug delivery technology, Aspirair, into Vectura in a deal worth around $5 million. ADL's European technology arm will buy a stake in European drug delivery company Vectura, as well as taking a seat on the board.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.